We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

By LabMedica International staff writers
Posted on 19 Nov 2024
Print article
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)

Bio-Techne Corporation (Minneapolis, MN, USA) and ALZpath, Inc. (Carlsbad, CA, USA) have entered into a strategic partnership to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. By running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system, researchers will be able to detect the pTau217 signal in less invasive sample collection types, such as plasma samples, in just 90 minutes without any manual intervention, improving efficiency, scalability, and precision while providing the required information to help accelerate clinical decisions.

"Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field."

"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."

Related Links:
Bio-Techne Corporation

ALZpath, Inc.

Gold Member
Turnkey Packaging Solution
HLX
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
CMV QC
Inactivated Cytomegalovirus High Control
New
Entamoeba Test
RIDASCREEN Entamoeba Test

Print article

Channels

Hematology

view channel
Image: The new test could improve specialist transplant and transfusion practice as well as blood banking (Photo courtesy of NHS Blood and Transplant)

New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape

The release of oxygen by red blood cells is a critical process for oxygenating the body's tissues, including organs and muscles, particularly in individuals receiving large blood transfusions.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The iFAST reader scans 5000 individual bacteria with each sample analyzed in less than a minute (Photo courtesy of iFAST)

High-Throughput AST System Uses Microchip Technology to Rapidly Analyze Bacterial Samples

Bacteria are becoming increasingly resistant to antibiotics, with resistance levels ranging from 20% to 98%, and these levels are unpredictable. Currently, antimicrobial susceptibility testing (AST) takes... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.